Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)

To see complete record on, please visit this link

Id: NCT01304147

Organisation Name: Icahn School of Medicine at Mount Sinai

Overal Status: Completed

Start Date: October 2011

Last Update: February 8, 2017

Lead Sponsor: James Murrough

Brief Summary: The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).

  • Major Depressive Disorder

Total execution time in seconds: 0.31273889541626